Tissue Regenix Group PLC (LON:TRX) has opened another door in the US wound-care market after it signed a contract with a group purchasing organisation, Premier Inc.
Group purchasing organisations allow businesses to come together to order products in bulk and benefit from the discounts offered for larger orders.
Premier is a US-based healthcare improvement GPO that has around 3,600 hospitals and 120,000 other healthcare providers on its books.
All of these will now have contracted access to Tissue Regenix’s DermaPure wound care product.
DermaPure was awarded the contract under a breakthrough technology agreement, which Premier only awards after a review process determines the new product offers unique benefits compared to other products its companies have access to.
“Approval under Premier's breakthrough technology agreement marks a significant milestone for DermaPure,” said chief executive Antony Odell.
“This confirms the unique characteristics of our patented dCELL technology, the powerful clinical evidence we have collected, and the remarkable outcomes it achieves in real world clinical situations.”
DermaPure is a graft designed to replicate the human skin as closely as possible and is used to cover and help heal wounds.